Exhibit 99.1 Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer - Presented nonclinical data demonstrating the superior therapeutic effects of gedatolisib compared to other PI3K/AKT/mTOR inhibitors at the 2023 SABCS - Raised $65 million from the sale of equity; expect cash, cash equiva ...